Institution
Shanghai Jiao Tong University
Education•Shanghai, Shanghai, China•
About: Shanghai Jiao Tong University is a education organization based out in Shanghai, Shanghai, China. It is known for research contribution in the topics: Population & Cancer. The organization has 157524 authors who have published 184620 publications receiving 3451038 citations. The organization is also known as: Shanghai Communications University & Shanghai Jiaotong University.
Topics: Population, Cancer, Microstructure, Cell growth, Metastasis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Zhang et al. as discussed by the authors designed three types of low-level statistical features in both spatial and frequency domains to quantify super-resolved artifacts, and learned a two-stage regression model to predict the quality scores of super-resolution images without referring to ground-truth images.
338 citations
••
TL;DR: The results support the role of FGF21 as a key regulator of hepatic lipid metabolism in humans, and suggest that serum FGF 21 can be potentially used as a biomarker for NAFLD.
337 citations
••
TL;DR: In this article, Euro V diesel fuel, biodiesel, and ethanol-biodiesel blends (BE) were tested in a 4-cylinder direct-injection diesel engine to investigate the combustion, performance and emission characteristics of the engine under five engine loads at the maximum torque engine speed of 1800rpm.
337 citations
••
TL;DR: Mental health problems and resilience co-existed in children and adolescents during the COVID-19 outbreak and open communication between parents and children about the pandemic should be encouraged to help children and teenagers cope with mental health problems in public health crisis.
337 citations
••
Shanghai Jiao Tong University1, Tianjin Medical University2, Zhengzhou University3, Peking Union Medical College Hospital4, Guangzhou Medical University5, Peking Union Medical College6, Nanjing Medical University7, Shandong University8, Medical University of Vienna9, Xi'an Jiaotong University10, Capital Medical University11
TL;DR: Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival, suggesting that anlot inib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC.
Abstract: Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug’s efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment. Design, Setting, and Participants The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical trial designed to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. Patients from 31 grade-A tertiary hospitals in China were enrolled between March 1, 2015, and August 31, 2016. Those aged 18 to 75 years who had histologically or cytologically confirmed NSCLC were eligible (n = 606), and those who had centrally located squamous cell carcinoma with cavitary features or brain metastases that were uncontrolled or controlled for less than 2 months were excluded. Patients (n = 440) were randomly assigned in a 2-to-1 ratio to receive either 12 mg/d of anlotinib or a matched placebo. All cases were treated with study drugs at least once in accordance with the intention-to-treat principle. Main Outcomes and Measures The primary end point was overall survival. The secondary end points were progression-free survival, objective response rate, disease control rate, quality of life, and safety. Results In total, 439 patients were randomized, 296 to the anlotinib group (106 [36.1%] were female and 188 [64.0%] were male, with a mean [SD] age of 57.9 [9.1] years) and 143 to the placebo group (46 [32.2%] were female and 97 [67.8%] were male, with a mean [SD] age of 56.8 [9.1] years). Overall survival was significantly longer in the anlotinib group (median, 9.6 months; 95% CI, 8.2-10.6) than the placebo group (median, 6.3 months; 95% CI, 5.0-8.1), with a hazard ratio (HR) of 0.68 (95% CI, 0.54-0.87;P = .002). A substantial increase in progression-free survival was noted in the anlotinib group compared with the placebo group (median, 5.4 months [95% CI, 4.4-5.6] vs 1.4 months [95% CI, 1.1-1.5]; HR, 0.25 [95% CI, 0.19-0.31];P Conclusions and Relevance Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. This finding suggests that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC. Trial Registration ClinicalTrials.gov identifier:NCT02388919
337 citations
Authors
Showing all 158621 results
Name | H-index | Papers | Citations |
---|---|---|---|
Meir J. Stampfer | 277 | 1414 | 283776 |
Richard A. Flavell | 231 | 1328 | 205119 |
Jie Zhang | 178 | 4857 | 221720 |
Yang Yang | 171 | 2644 | 153049 |
Lei Jiang | 170 | 2244 | 135205 |
Gang Chen | 167 | 3372 | 149819 |
Thomas S. Huang | 146 | 1299 | 101564 |
Barbara J. Sahakian | 145 | 612 | 69190 |
Jean-Laurent Casanova | 144 | 842 | 76173 |
Kuo-Chen Chou | 143 | 487 | 57711 |
Weihong Tan | 140 | 892 | 67151 |
Xin Wu | 139 | 1865 | 109083 |
David Y. Graham | 138 | 1047 | 80886 |
Bin Liu | 138 | 2181 | 87085 |
Jun Chen | 136 | 1856 | 77368 |